Document ID: /roh_data/filtered/swiss_laws_in_ROHinterleaved.jsonl.gz/34992

This text was translated from EN into Rumantsch Grischun.

The FOPH shall collect data on medical treatments using narcotics containing an effective concentration of cannabis (medicinal cannabis products) that:a. are not authorised;b. are authorised but are prescribed for an indication other than the authorised indication and used in a form other than the authorised pharmaceutical form. The data is collected for:a. the scientific evaluation under Article 29a; andb. statistical analysis. The FOPH shall make the results of the statistical analysis available to:a. the cantonal executive authorities;b. the doctors involved in the treatment;c. research institutions that are interested. Inserted by No I of the FA of 19 March 2021, in force from 1. Aug. 2022 until  31 July 2029 (AS 2022 385; BBl 2020 6069).

Il UFSP retschertga las datas davart ils tractaments medicals cun narcotics che han effects dal tip da cannabis (medicaments da cannabis) e che:a. n’èn betg admess;b. èn admess, ma vegnan prescrits per in’autra indicaziun che l’indicaziun admessa ed applitgads en in’autra furma farmaceutica che la furma admessa. La retschertga da datas serva:a. a l’evaluaziun scientifica tenor l’artitgel 29a; eb. a l’evaluaziun statistica. Il UFSP metta a disposiziun ils resultats da l’evaluaziun statistica:a. a las autoritads executivas chantunalas;b. als medis ch’èn participads al tractament;c. als instituts da perscrutaziun interessads. Integrà tras la cifra I da la LF dals 19 da mars 2021, en vigur dal 1. d’avust 2022 fin ils 31 da fan. 2029 (AS 2022 385; BBl 2020 6069).